International Journal of Science and Research (IJSR)
ISSN: 2319-7064
Impact Factor 2024: 7.101

Cancer Antigen 15-3 (CA 15-3): A Paradigm of Biomarker Utility in Oncology

Shraddha Prabhu (Aditi Palav)[1], Dr. Rajashree Singh[2], Dr. Kunal Shukla[3]

[1]Laboratory of Native Antigens, Research and Development Division, Advy Chemical Private Limited, Thane 400604, Maharashtra, India
Corresponding Author Email: *aditipalav1201[at]gmail.com*

[2]Faculty of Science, Department of Biotechnology, Amity University, Mumbai, Bhatan-410206, Maharashtra, India.
Corresponding Author Email: *rsingh1[at]mum.amity.edu*

[3]Laboratory of Native Antigens, Research and Development Division, Advy Chemical Private Limited, Thane 400604, Maharashtra, India

Abstract: ***Cancer Antigen 15-3 (CA 15-3), a derivative of the MUC1 mucin, epitomizes the intricate interplay between tumor biology and clinical diagnostics. This high-molecular-weight glycoprotein, characterized by aberrant glycosylation, serves as a crucial biomarker in the surveillance of breast cancer. This review delves into the molecular intricacies of CA 15-3, elucidates the methodologies employed in its purification, and highlights its clinical applications. Challenges in assay standardization and the burgeoning role of advanced technologies in refining its diagnostic accuracy are also explored, offering a comprehensive discourse on this pivotal biomarker.***

Keywords: CA 15-3 Structure, Biomarker, Cancer Antigen 15-3

1. Introduction

In the realm of clinical oncology, biomarkers occupy a central position as harbingers of disease progression, therapeutic response, and prognostic outcomes. Among these, Cancer Antigen 15-3 (CA 15-3) emerges as a quintessential example, primarily utilized in breast cancer management. Derived from the MUC1 mucin—a glycoprotein with profound roles in cellular adhesion and immune modulation—CA 15-3 offers a window into the tumor microenvironment (Gendler et al., 1990; Hollingsworth et al., 2004). This review synthesizes current knowledge on CA 15-3, accentuating its structural nuances, purification strategies, and translational applications.

2. Molecular Architecture of CA 15-3

CA 15-3 is not a singular molecule but rather a composite entity arising from the extracellular domain of MUC1, a highly glycosylated transmembrane protein (Hanisch et al., 2000; Baldus et al., 2004).

a) **Structural Features:** The core polypeptide of MUC1, enriched in serine and threonine residues, forms a scaffold for O-linked oligosaccharides. The tandem repeat region (TRR), consisting of a 20-amino-acid motif, is the primary site of glycosylation and harbours tumour-associated epitopes (Hilkens et al., 1992; Gendler et al., 1995).
b) **Pathophysiological Implications:** In malignancies, aberrations in glycosylation confer oncogenic advantages, including evasion of immune surveillance, enhancement of metastatic potential, and resistance to apoptosis (Apostolopoulos et al., 1994; Singh et al., 2007). Understanding the biochemical idiosyncrasies of CA 15-3 is imperative for the development of robust diagnostic assays and therapeutic interventions.

3. Methodologies for Purification and Detection

The purification of CA 15-3 from complex biological matrices such as serum or tissue lysates is a technically demanding endeavour, necessitating precise and reproducible methodologies (Haider et al., 2018).

3.1 Purification Strategies

Immunoaffinity Chromatography: Leveraging monoclonal antibodies specific to MUC1 epitopes, this technique achieves unparalleled specificity in isolating CA 15-3 (Winthrop et al., 1999; Haider et al., 2018).

Lectin Affinity Chromatography: Capitalizes on the unique glycosylation patterns of CA 15-3, offering an orthogonal approach to immunoaffinity techniques (Hanisch et al., 2000).

-Size-Exclusion Chromatography and Ultracentrifugation: Complementary methods that exploit the molecular weight and density characteristics of CA 15-3 (Haider et al., 2018).

3.2 Analytical Techniques for Detection

Enzyme-Linked Immunosorbent Assay (ELISA): The workhorse of CA 15-3 quantification, ELISA combines sensitivity with scalability, enabling widespread clinical application (Cheung et al., 2009; Haider et al., 2018).

Western Blotting: Though labor-intensive, this technique provides confirmatory insights into the molecular weight and epitope integrity (Bramwell et al., 1986).

Mass Spectrometry: An emerging paradigm for structural and quantitative analysis, mass spectrometry holds promise for unraveling the glycoproteomic landscape of CA 15-3 (Dwek et al., 2008).

4. Clinical Applications: From Bench to Bedside

4.1 Oncological Applications

Breast Cancer Management: The utility of CA 15-3 as a biomarker in breast cancer is unparalleled, particularly in monitoring therapeutic response and detecting disease recurrence. Elevated serum levels are correlated with tumor burden, offering a non-invasive proxy for disease dynamics (Colomer et al., 1989; Kandylis et al., 1990; Cheung et al., 2009).

Multi-Cancer Utility: Beyond breast cancer, CA 15-3 exhibits potential in the diagnosis and monitoring of other malignancies, including ovarian, pancreatic, and non-small-cell lung cancer (Wu et al., 2014; Manuali et al., 2012).

4.2 Limitations in Diagnostic Specificity

While CA 15-3 is predominantly associated with malignancies, its elevation in benign conditions such as hepatic dysfunction and inflammatory diseases necessitates a nuanced interpretation of results (Laidi et al., 2014; Adachi et al., 2015). The integration of CA 15-3 into multi-marker panels is critical for enhancing diagnostic specificity and sensitivity.

5. Challenges and Future Horizons

Despite its clinical significance, CA 15-3 is not without limitations.

- **Analytical Variability:** Disparities in assay platforms and lack of standardization pose significant challenges to inter-laboratory comparability (Haider et al., 2018).
- **Heterogeneity of Expression:** Tumor heterogeneity and the dynamic nature of glycosylation hinder the development of universally applicable diagnostic thresholds (Singh et al., 2007).
- **Emerging Technologies:** Advances in nanotechnology, bioinformatics, and glycoproteomics are poised to revolutionize CA 15-3 detection, enabling real-time monitoring and integration into precision oncology frameworks (Grzywa et al., 2014).
- **Research Frontiers:** The intersection of CA 15-3 biology with immuno-oncology offers tantalizing prospects for therapeutic innovation. Antibody-drug conjugates (ADCs) targeting MUC1 epitopes and vaccine strategies are under exploration, heralding a new era of biomarker-guided therapeutics (Winthrop et al., 1999; Singh et al., 2007).

6. Conclusion

CA 15-3 exemplifies the dual utility of biomarkers in bridging basic science and clinical practice. While it has cemented its role in the management of breast cancer, the full spectrum of its potential remains to be harnessed. By addressing the challenges of standardization and leveraging next-generation technologies, CA 15-3 could serve as a cornerstone in the evolving landscape of personalized oncology.

References

[1] Bramwell M, Wisema G, Shotton D, 1986. Electron-microscopic studies of the CA antigen-epitectin. J Cell Sci.
[2] Colomer R, Ruibal A, Genolla J, 1989. Circulating CA 15-3 antigen levels in non-mammary malignancies. Br J Cancer.
[3] Gendler SJ et al., 1990. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.
[4] Kandylis K et al., 1990. Diagnostic significance of the tumour markers CEA, CA 15-3, and CA 125 in malignant effusions in breast cancer. Ann Oncol.
[5] Hilkens J et al., 1992. The structure of cell-associated mucin-like molecules and their adhesion modulating property. Trends Biochem Sci.
[6] Apostolopoulos V et al., 1994. Cellular mucins: Targets for immunotherapy. Crit Rev Immunol.
[7] Haider S et al., 2018. Simplified approach for in vitro production and purification of CA 15-3. Int J Biol Macromol.

Author Profile

Shraddha Prabhu (Aditi Palav), MSc. Biotechnology, Assistant Manager at ADVY Chemical Pvt. Ltd.
Email: *aditipalav1201[at]gmail.com*

Shraddha Prabhu (Aditi Palav) has over 12 years of experience in the downstream purification of protein molecules for diagnostic applications, specializing in both native and recombinant proteins. Specialized in purification of cancer biomarkers from native human biological waste as initial source. For the past 6 years, she has been associated with ADVY Chemical Pvt. Ltd., where she has played a pivotal role in protein/enzyme purification process development, enzyme characterization, protein refolding and stability, and scale-up of purification processes. Her technical expertise encompasses chromatography, membrane separation techniques, and various biochemical and molecular methods. She has successfully developed and optimized cost-effective purification processes for a range of protein sources, including microbial proteins from fermentation broths. In addition to process development, Shraddha Prabhu (Aditi Palav) has extensive experience in quality control analysis of purified protein/enzyme products and ensures regulatory and statutory compliance within her organization. Her work emphasizes the importance of good laboratory practices (GLP) and team collaboration, supporting innovative research in protein purification and diagnostic biotechnology.

Publications:

1) Badgujar, S. B., Rane, A. M., **Palav, A. A.**, Kumar, S., Dabholkar, A. P., Sawant, S. A., Tandale, B. U., Daftary, S. B., Sawant, N. P., & Lala, S. (2022). A simple scheme for large scale purification of urine-derived Bence Jones Kappa protein. Journal of Chromatography B, 1210, 123452. https://doi.org/10.1016/j.jchromb.2022.123452A

Rajshri Singh, Ph.D., Assistant Professor-I, Specialization: Tumor Microenvironment, Cancer Immunology
Email: *rsingh1[at]mum.amity.edu*

Dr. Rajshri Singh is an accomplished academic and researcher with over 3 years of experience as an Assistant Professor of Biotechnology at the Amity Institute of Biotechnology, Mumbai. She holds a Ph.D. in Life Sciences and an M.Sc. in Biotechnology. Dr. Singh has demonstrated excellence in teaching a broad spectrum of courses, including Animal Biotechnology, Immunology, Frontiers in Biotechnology, Agricultural Biotechnology, Human Physiology,

Food Safety and Regulations, and Biopharma QC and Regulations. Dr. Rajshri Singh has done her B.Sc. in Biotechnology with Distinction from Maharani College, Jaipur and M.Sc. in Biotechnology with Distinction from the ICG College, University of Rajasthan, Jaipur. She completed her Ph.D. in Life Sciences from Homi Bhabha National Institute, Bhabha Atomic Research Centre (BARC), Mumbai with Department of Atomic Energy (DAE) Fellowship. After completion of her PhD, she worked for 2 years in Advanced Centre For Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre in DBT-ICGC-India Project. Currently, she is working as an Assistant Professor at Amity Institute of Biotechnology, Amity University Maharashtra. In her doctoral research at BARC, Mumbai, she studied the interaction of immune system cells and its mediators with growth and survival of cancer cells. The work described TGF-β-ROS-ATM-CREB signaling axis in macrophage mediated migration of human breast cancer cells. The work also described significant alterations of the novel 15 gene signature identified from macrophage-tumor interactions in breast cancer. She studied the interaction of inflammation, DNA damage and survival signaling in breast cancer patients. In DBT-ICGC India Project, the complex profile of immune infiltrating cells subsets in Oral squamous cell carcinoma patients was studied along with its correlation with the survival and mutation burden of the patients. She is actively involved in teaching courses at UG, PG and PhD level related to Animal Biotechnology and Immunology. Dr. Singh is a qualified scholar in multiple competitive examinations, having cleared CSIR-UGC NET JRF, DBT-JRF, DAE-JRF, and GATE. She also served as an STS Fellow at the prestigious International Cancer Genome Consortium (ICGC-India) Project from 2016 to 2018, contributing to groundbreaking cancer genomics research.

Selected Publications:

1) **Singh R**, Shankar BS, Sainis KB. (2014). TGF-β1-ROS-ATM-CREB signaling axis in macrophage mediated migration of human breast cancer MCF7 cells. Cellular Signalling, 2014. 26(7):1604-15. (IF: 4.31)
2) **Rajshri Singh**, Priya Dagar, Shyama Pal, Bhakti Basu, Bhavani S Shankar. (2018). Significant alterations of the novel 15 gene signature identified from macrophage-tumor interactions in breast cancer. Biochimica et Biophysica Acta (BBA) - General Subjects, 2018. 1862 (3): 669-683. (IF: 3.77)

Kunal Shukla, Ph.D, Principle Scientist,
Specialization: BioChemistry
Email: kunal.shukla[at]advychemical.com

Dr. Kunal Shukla is an experienced professional with 17 years in the field of downstream purification of proteins from native, recombinant, and cell culture-based sources. He holds a Ph.D. in Biochemistry from Savitribai Phule Pune University (2017), with his research focused on the isolation of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and its expression in *E. coli*. Currently, Dr. Shukla serves as Principal Scientist at Advy Chemical Pvt. Ltd., where he leads a team of 20, including 12 scientists. Prior to this, he was Head of R&D DSP at Yashraj Biotechnology Ltd. (2010–2020), where he represented the company at MEDICA 2015 in Germany. He has also completed a General Management Program at IIM Kozhikode and worked as a Scientific Officer at Gennova Biotechnology Ltd. and a Research Associate at USV Ltd.

Selected publications:

1) **Kunal Shukla**, Shamkant Badgujar, Paresh Bhanushali, Sushma Sabharwal; Simplified purification approach of urinary neutrophil gelatinase-associated lipocalin by tangential flow filtration and ion exchange chromatography. Journal of chromatography. B, 2017 March; 1051:68-74 4 |
2) Bhupesh C. Mali, Shamkant B. Badgujar, **Kunal K. Shukla**, Paresh B. Bhanushali A novel approach for the chromatographic purification and peptide mass fingerprinting of urinary free light chains. Int. J. Biol. Macromol. 2017 Feb; 95:331- 339.
3) Rodrigues AV, Puri CP, Bhanushali PB, **Shukla KK**, Roychoudhury S, Badgujar SB Development of an indirect immunofluorescence-based assay for diagnosis of ulcerative colitis in Indian population. Immunol. Lett. 2017 Jan; 181:20-25.
4) **Kunal Shukla**, Paresh Bhanushali, Anuj Kumar Gupta and Sushma Sabharwal; Purification and comparative study of NGAL isoforms from neutrophil and kidney origin suggest its different roles under different stress conditions. Int. J. Pharm. Bio. Sci. 2014 July; 5 (3): (B) 622 – 633.
5) **Kunal Shukla**, Paresh Bhanushali, Prerna Rathod and M.M Tripathi; A novel chromatographic purification method for high pure CA 15 3. Int. J. Biotech. Bioeng. Res. 2013; 4 (2) 145-151.